AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00430092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06212102
Drug: Progestin primed ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
Trial: NCT05372120
Drug: ICP-192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
Trial: NCT05210790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05369858
Drug: [14C] SKLB1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
Trial: NCT04964453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
Trial: NCT05128175
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
RxNorm normalized name: carbidopa / levodopa Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
Trial: NCT05862064
Drug: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy in combination with carrelizumab
Trial: NCT05862064
Drug: epirubicin,cyclophosphamide,paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy
Trial: NCT05017610
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05873465
Drug: Sedation with Midazolam, Fentanyl, and Propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
Trial: NCT05876039
Drug: Initial remifentanil effect-site concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different initial remifentanil effect-site concentration
Trial: NCT05543590
Drug: Plasmapheresis
RxNorm normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 sessions of plasma exchanges
Trial: NCT06183008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
Trial: NCT04010266
Drug: multi-modality pain management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
Trial: NCT05111366
Drug: TQB2450 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
Trial: NCT05182047
Drug: Sinecod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinecod syrup will be administered orally.
Trial: NCT06468709
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
Trial: NCT04060407
Drug: CD24Fc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
Trial: NCT04262895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06228430
Drug: Zovirax™ 800 mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zovirax™ 800 mg Tablet (Reference Drug)
Trial: NCT05850936
Drug: Assigned Interventions: IOP-lowering eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the first choice for treatment.~1. If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added; If the IOP reduction of 10% is then not achieved at 1 month after adding Brinzolamide 1%, Alphagan 0.2% or Alphagan-P 0.15% eye drops will be added.~2. If an individual is allergic to Xalacom or feels uncomfortable, the eye drops will be switched to Azarga eye drops (combination drops, fixed Brinzolamide with Timolol); If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added.~3. The effect of IOP lowering would be assessed every week after applying each medication until the target IOP was achieved and follow up the schedule time. If an IOP reduction of 10% is then not achieved, the individual will be excluded from the study.
Trial: NCT05148481
Drug: BIIB104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT05148481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT05306132
Drug: ASKC202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Forms: Tablets; Administration: Oral administration
Trial: NCT06207539
Drug: hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company
RxNorm normalized name: n-butyl acrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
Trial: NCT05724849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm/group description.
Trial: NCT05442515
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
Trial: NCT06267963
Drug: Oral [14C]PF-07220060
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.
Trial: NCT04753164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Trial: NCT06267963
Drug: IV [14C] PF-07220060
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
Trial: NCT06476223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
Trial: NCT05510323
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RAS blockade as much as tolerated or allowed
Trial: NCT05510323
Drug: Prednisolone plus Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS blockade as much as tolerated or allowed
Trial: NCT05826964
Drug: AI+CDK4/6i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib
Trial: NCT05826964
Drug: SERD+CDK4/6i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib
Trial: NCT05826964
Drug: mTOR inhibitor + AI
RxNorm normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Trial: NCT05826964
Drug: mTOR inhibitor + SERD
RxNorm normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Trial: NCT05826964
Drug: mTOR inhibitor + Selective estrogen receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Trial: NCT05826964
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
Trial: NCT05826964
Drug: Oral SERD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Trial: NCT06226727
Drug: BR1019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06226727
Drug: BR1019-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06226727
Drug: BR1019-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06264388
Drug: DB107-RRV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
Trial: NCT06264388
Drug: DB107-FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
Trial: NCT05874180
Drug: DW6013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition
Trial: NCT03594162
Drug: iC9-CAR19 cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of two dose levels will be given: 1 x 10\^5 or 5 x 10\^5
Trial: NCT03594162
Drug: AP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
Trial: NCT03594162
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
Trial: NCT00605774
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
Trial: NCT00605774
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
Trial: NCT05409235
Drug: OTT166
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive OTT166 ophthalmic solution
Trial: NCT05861791
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
Trial: NCT05861791
Drug: ketorolac tromethamine with nefopam hydrochloride
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
Trial: NCT04935021
Drug: ATTR-CM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment
Trial: NCT04709575
Drug: REGN5714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT04709575
Drug: REGN5715
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT04709575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo that replaces REGN5713-5714-5715
Trial: NCT05953740
Drug: MK-5720
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection
Trial: NCT05953740
Drug: Placebo to MK-5720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IM Injection matched to MK-5720
Trial: NCT06152172
Drug: KYV-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
Trial: NCT01395940
Drug: KLH-2109
RxNorm normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06152172
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
Trial: NCT05782881
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment and management according to the guidelines
Trial: NCT05324410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-840 for oral administration.
Trial: NCT05409027
Drug: SPI-62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI-62 is supplied as 1 mg tablets for oral dosing.
Trial: NCT05112692
Drug: Estradiol Valerate and progesterone
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
Trial: NCT05001243
Drug: Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBOHB to improve uncorrected near vision in healthy presbyopic patients
Trial: NCT06371222
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: controlled group
Trial: NCT05903131
Drug: Progestin
RxNorm normalized name: Progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Released via the levonorgestrel-releasing IUD.
Trial: NCT05755191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Doses
Trial: NCT05041790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
Trial: NCT04904185
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
Trial: NCT05225961
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
Trial: NCT00006412
Drug: Pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06259331
Drug: SPN-812 (600mg, QD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER
Trial: NCT04817228
Drug: EscharEx (EX-02 formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
Trial: NCT00002188
Drug: Alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06484608
Drug: Isotonic Saline with Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
Trial: NCT06497049
Drug: GP40221
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for Subcutaneous Administration 1.34 mg/ml
Trial: NCT04847674
Drug: TEV-53275 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous (sc) injection
Trial: NCT04847674
Drug: TEV-53275 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous (sc) injection
Trial: NCT04847674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching subcutaneous (sc) placebo injection
Trial: NCT06091332
Drug: Starch flake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
Trial: NCT05233566
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluid acting as a placebo
Trial: NCT06416865
Drug: AJU-C52L, AJU-C52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.
Trial: NCT06416865
Drug: C52R1L, C52R1M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.
Trial: NCT04952194
Drug: Carbidopa and Levodopa Controlled Release Tablets
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
Trial: NCT06014073
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.